Navigation Links
Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug
Date:4/18/2013

TAMPA, Fla., April 18, 2013 /PRNewswire/ -- Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza.

(Logo:  http://photos.prnewswire.com/prnh/20100201/FL47022LOGO )

The Phase 3 clinical trial has been initiated in the United States, will continue in Australia and New Zealand in the southern hemisphere and is expected to be completed during the 2013-2014 flu season in the northern hemisphere.

"There is a pressing need for new drugs to treat influenza," said Jean-Francois Rossignol , M.D., Ph.D., Chairman and Chief Science Officer of Romark. "This trial is designed to provide data required to support an application for approval to market NT-300 for treatment of influenza.  We are also addressing the opportunity to combine treatment with NT-300 and oseltamivir in an effort to further improve treatment outcomes and mitigate the risk of oseltamivir resistance."

The clinical trial will enroll 1,400 patients with fever and other symptoms of influenza. Patients are being randomly assigned to receive treatment with either NT-300, placebo (sugar pill), oseltamivir (Tamiflu®) or NT-300 plus oseltamivir. The primary objectives of the study are to demonstrate that (i) NT-300 reduces the duration of symptoms compared to treatment with placebo and (ii) NT-300 co-administered with oseltamivir reduces the duration of symptoms compared to NT-300 alone and to oseltamivir alone.

After completing this clinical trial, Romark plans to submit a New Drug Application seeking FDA approval to market NT-300 administered alone or in combination with oseltamivir as a treatment of acute uncomplicated influenza.

Currently, there are only two classes of drugs approved in the United States for treating influenza, and only the neuraminidase inhibitors, oral Tamiflu® (oseltamivir) and inhaled Relenza® (zanamivir), are recommended for use. There has not been a new drug approved in the United States for treating influenza since Tamiflu® and Relenza® were approved in 1999. New drugs with different mechanisms of action could be important in overcoming drug resistance and providing better treatment for patients with influenza.

The Phase 3 clinical trial of NT-300 will be fully funded by the U.S. Department of Health and Human Services (HHS)/Office of the Assistant Secretary of Preparedness and Response (ASPR)/Biomedical Advanced Research and Development Authority (BARDA) under contract HHSO100201300004C. The value of the cost plus fixed-fee contract is up to $44 million.

For further information on this clinical trial, visit http://www.clinicaltrials.gov/ct2/show/NCT01610245.

About Influenza

Influenza (flu) is a contagious respiratory illness caused by influenza viruses.  According to the United States Centers for Disease Control and Prevention (CDC), seasonal flu affects, on average, 5% to 20% of the United States population per year leading to approximately 200,000 hospitalizations and 3,000 to 49,000 deaths.  Pandemic influenza refers to a global outbreak of flu caused by a new emerging influenza virus that has the ability to infect and be passed among humans and to which there is little or no immunity.  The threat of pandemic influenza is a major concern because of its potential effect on human life as well as the economy, national security and the basic functioning of society.

About NT-300

NT-300, a controlled release tablet for oral administration containing 300 mg of nitazoxanide (NTZ) as active ingredient, is an investigational new drug being developed by Romark Laboratories for treatment of influenza. NTZ inhibits replication of a broad range of influenza viruses in cell culture assays, including oseltamivir- and amantadine-resistant strains, as well as other respiratory viruses that may cause flu-like symptoms in humans including the paramyxoviridae and the coronaviridae.  In cell culture assays, NTZ and oseltamivir act synergistically in inhibiting replication of influenza viruses.  In a Phase 2b/3 clinical trial conducted in the United States during the 2010-2011 influenza season, NT-300 administered 600 mg orally twice daily for 5 days reduced the duration of symptoms of acute uncomplicated influenza compared to a placebo and reduced viral titers in nasal swabs collected during treatment.

About Romark Laboratories

Romark Laboratories, L.C. is a biopharmaceutical company committed to the discovery and development of innovative small molecule drugs for treating infectious diseases and cancers. The company is developing a new class of broad-spectrum antiviral drugs called thiazolides. Romark markets Alinia® (nitazoxanide) tablets, 500 mg and Alinia® (nitazoxanide) for Oral Suspension, 100 mg/5 mL in the United States.


'/>"/>
SOURCE Romark Laboratories, L.C.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Laboratories Awarded Contract For Late-Stage Development Of New Influenza Drug
2. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
3. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
4. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
5. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
6. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
7. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
8. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
9. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
10. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
11. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
Breaking Medicine News(10 mins):